BlueRock licenses cell therapy


United States

BlueRock Therapeutics LP has exercised an option and gained exclusive rights to a cell therapy derived from induced pluripotent stem cells (iPSC) for the treatment of primary photoreceptor diseases. The product, OpCT-001, was developed in collaboration with Fujifilm Cellular Dynamics Inc, a manufacturer of human iPSCs and iPSC-derived cells, and Opsis Therapeutics LLC.